Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement

Inclusion Criteria: * Subject has provided informed consent/assent prior to initiation of any study-specific activities/procedures * Ambulatory postmenopausal women and men with osteoporosis * Scheduled to undergo elective THR due to osteoarthritis of the hip * Received at least 2 doses of denosumab 60 mg subcutaneously over 18 months * Last dose of denosumab within 6 months of scheduled THR Exclusion Criteria: * Received treatment for osteoporosis other than denosumab in one year prior to THR * Subjects with current diagnosis of any of the following conditions are excluded * Current, uncontrolled hypo- or hyperthyroidism (subjects who have controlled hypo- or hyperthyroidism may be eligible, provided that they have been on a stable therapy for at least 3 months \[per subject report\]) * Current, hypo- or hyperparathyroidism * Osteomalacia * Paget's disease of bone * Other bone diseases which affect bone metabolism (eg, osteopetrosis, osteogenesis imperfecta) * Severe chronic kidney disease (CKD), defined as CKD stage 4 or greater * Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma) * Self-reported alcohol or drug abuse within the previous 12 months * Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s) * Other investigational procedures while participating in this study are excluded * Subject has …